United States Pharmacopeia (USP), an independent, scientific nonprofit organization, is pleased to announce the acquisition of Pharmatech Associates, Inc. By adding Pharmatech Associates expertise, USP further advances its more than 200-year mission to help ensure access to quality medicines by extending services that assist manufacturers to meet global quality standards across the drug and product lifecycle.
The global medicine supply chain is a complex marketplace of manufacturers, suppliers, and distributors from many countries. Making it more resilient requires a multi-faceted approach. The acquisition of Pharmatech supports our commitment to expand our capabilities to strengthen the supply chain of quality medicines, builds on our longstanding work with regulators and manufacturers globally to solve some of the most critical and challenging problems in the industry, and helps ensure patients have access to the medicines that they need. Pharmatech helps manufacturers satisfy global regulatory requirements to bring products to market, scale up manufacturing, effectively manage quality control, and remediate quality problems in a rapidly changing environment.
“The drug recalls we’ve seen in recent years and the supply chain challenges underscored by the COVID-19 pandemic have raised concerns about ongoing quality and safety issues,” said Ronald T. Piervincenzi, Ph.D., USP’s Chief Executive Officer. “This announcement positions us to continue to strengthen the supply chain and extend our many years of collaborating with global regulators and manufacturers to ensure the quality of medicines as we have done with our donor-funded work and ingredient verification services for API and excipients.”
“We are pleased to share with USP the goal of helping manufacturers to bring safe and effective treatments to patients who need them. We bring a high standard of service to our clients, grounded in scientific excellence, and designed to meet the future compliance, quality, and business performance needs of the global healthcare industry,” Bikash Chatterjee, CEO and Chairman, Pharmatech Associates.
Pharmatech Associates and its employees will continue its day-to-day operations independent of USP.